Listen to article
6:44Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
Let’s be honest, for the last few decades, antibiotics have been the forgotten corner of the pharmaceutical world. While Big Pharma chased the golden goose of chronic disease treatments, drugs you take for a lifetime, the humble antibiotic was left to gather dust. It was a simple, if rather cynical, calculation. Why bother with a cure you take for a week when you can sell a treatment that lasts for thirty years? But now, it seems the chickens, or rather the superbugs, are coming home to roost. GSK’s new gonorrhoea treatment getting a priority nod from the FDA is, to me, a signal flare in the dark. It suggests the grown-ups are finally paying attention.
You’ve probably seen the headlines, but have you really let the numbers sink in? We are, without a shred of hyperbole, staring down the barrel of a post-antibiotic era. Already, around 700,000 people globally die each year from infections that our best drugs can no longer touch. Projections suggest that figure could climb to a staggering 10 million by 2050. That’s more than cancer kills today. This isn't some distant, hypothetical threat, it's a slow-motion disaster unfolding right now, undermining everything from routine surgery to chemotherapy.
For an investor, however, a crisis of this magnitude presents a peculiar sort of opportunity. When a problem becomes too big to ignore, the money required to solve it eventually has to show up. The combination of a desperate medical need and a field largely abandoned by the giants creates a rather interesting vacuum for those with the nerve to fill it.
The real game-changer here is the regulatory environment. When a body like the FDA grants a ‘priority review’, as it has for GSK, it’s not just a procedural tick box. It’s a clear statement of intent. It means they are slashing the approval timeline from a year or more down to a mere six to eight months. Why? Because they recognise the urgency. They know that our defences against evolving bacteria are crumbling.
For an investor, this is gold dust. One of the biggest risks in biotech is the agonisingly long and uncertain wait for regulatory approval. An accelerated pathway doesn't guarantee success, of course, but it significantly shortens the timeline to a potential return and reduces the period your capital is at risk. It’s the closest thing you’ll get to a government agency telling you where to look.
With the behemoths of the industry looking elsewhere, the stage has been left to smaller, more agile biotech firms. These aren't companies simply tinkering with old formulas. They are developing entirely new ways to attack bacteria. You have firms like Acurx Pharmaceuticals, which is working on mechanisms that target bacterial DNA in a way that makes it incredibly difficult for resistance to develop. Then there are others, like SPERO Therapeutics or Iterum Therapeutics, each tackling the problem from a different, innovative angle.
This is where the real potential lies. It’s a compelling narrative, one that forms the basis of investment themes like Targeting Superbugs: The Next Wave Of Antibiotics. The investment case rests on this convergence of urgent need, regulatory tailwinds, and a surprisingly uncrowded field.
Now, let’s not get carried away. Investing in biotechnology is not for the faint of heart. It is a notoriously volatile sector where dreams can, and frequently do, turn to dust overnight. Clinical trials are a minefield, and a single disappointing result can send a share price plummeting. Bacteria are a formidable enemy, and there is no guarantee that these new approaches will be the silver bullet we hope for. This is an area for investors who understand risk and have the patience to see a long-term thesis play out. The potential rewards are significant, but so are the pitfalls.
View the full Basket:Targeting Superbugs: The Next Wave Of Antibiotics
View the full Basket:Targeting Superbugs: The Next Wave Of Antibiotics
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
